Objective/background: Management of Wilms tumor (WT) in children depends on a multidisciplinary approach to treatment, and outcomes have significantly improved as reported by cooperative group clinical trials. Here, we review the clinical outcomes of patients with WT and identify challenges and barriers encountered in multidisciplinary management outside of cooperative clinical trials. Methods: We retrospectively reviewed the clinical records of 35 children with WT treated between April 2002 and June 2013 at the Children's Cancer Institute in Lebanon. Results: Upfront resection was performed in 23 cases. Biopsies were performed for Stage V tumors (n = 4), those with unresectable tumors or inferior vena caval thrombus (n = 5), and patients who had partial surgery performed elsewhere prior to presentation (n = 2). One patient died due to toxicity prior to surgery. The tumor was Stage I in eight patients, Stage II in five patients, Stages III and IV in nine patients each, and bilateral (Stage V) in four patients. Adherence to The National Wilms Tumor Study-5 recommendations was adequate. At the time of analysis, 30 patients were free of disease and four patients had relapse-all having metastatic disease initially. Conclusion: The National Wilms Tumor Study-5 therapy resulted in favorable outcomes in children with nonmetastatic Wilms tumor in the setting of a multidisciplinary approach to therapy and resolution of financial barriers to medical care. Upstaging due to prior intervention and lung radiation therapy to all those with computed tomography-detected lung nodules may both http://dx
Introduction
Nephroblastoma (Wilms tumor; WT) is the most common pediatric renal tumor [1] , thought to arise from foci of persistent metanephric cells referred to as nephrogenic rests or nephroblastomatosis [2] . The outcome of WT has improved significantly over the past few decades; the 5-year survival rate has improved from 20% in the 1960s to over 90% in the current decade [3] [4] [5] . This improvement is due primarily to a multidisciplinary approach to treatment, and to a series of cooperative clinical trials aiming at optimizing therapy and risk stratification, led by two large study groups: the North American Children's Oncology Group via The National Wilms Tumor Study (NWTS) group, and the European Societe Internationale D'oncologie Pediatrique (SIOP) group. However, despite the impressive improvements in outcome, retrospective reviews of outcomes from developing countries have shown poorer results [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Factors that are thought to contribute to this disparity include late presentation, malnutrition, poverty leading to abandonment of treatment, and lack of multidisciplinary collaboration [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . In this study we aimed to determine the characteristics and outcomes of patients with WT treated at a multidisciplinary center in Lebanon, and to identify successes and barriers in implementing established treatment protocols and risk stratification for this disease when applied in a multidisciplinary setting outside of a cooperative clinical trial, and after financial barriers to therapy are overcome by a local fundraising body.
Materials and methods
This retrospective study was approved by the Institutional Review Board at the American University of Beirut Medical Center, Beirut, Lebanon. All patients with Wilms tumor treated at the Children's Cancer Institute at the American University of Beirut Medical Center between April 2002 and June 2013 were identified, and the medical records were retrospectively reviewed. Data collected included the age at diagnosis, sex, tumor site, size, extent, stage, treatment received, complications, and outcome. The initial workup for all patients included history, physical examination, and laboratory blood tests including kidney function tests. Staging studies included computed tomography (CT) scans of the chest, abdomen, and pelvis, with oral and intravenous contrast administration, and in some cases plain X-ray of the chest. Nephrectomy and complete tumor resection was performed upfront whenever feasible; upfront tumor biopsy was restricted to patients with bilateral tumors or those who had extensive regional disease precluding attempts at complete resection. Patients with upfront biopsy received neo-adjuvant chemotherapy, with delayed surgical resection.
Risk stratification and treatment planning were unified and based on the NWTS-5 protocol. Per this plan, patients with Stage I and favorable histology Stage II tumors receive regimen EE4A consisting of vincristine and actinomycin-D for 18 weeks [20] ; those with unfavorable histology Stage II tumors or favorable histology Stage III and IV tumors receive regimen DD4A consisting of vincristine, actinomycin-D, and doxorubicin for 24 weeks [20] ; and those with Stage II-IV tumors with diffuse anaplasia received regimen I which includes vincristine, cyclophosphamide, etoposide, and doxorubicin for 24 weeks [21] . Patients received radiation therapy (flank, whole abdomen, lung, metastatic sites) as per the NWTS-5 protocol; specifically, patients with Stage III focal tumor received focal abdominal radiation to 10.8 Gy; those with tumor spill, positive peritoneal cytology, or extensive lymphadenopathy received whole abdomen radiation to 10.8 Gy; patients with lung metastases received radiation to the lungs to 12 Gy, and those with bulky extra-abdominal metastases received radiation to that site, as needed. After finishing treatment, all patients were followed up regularly with physical examination, imaging with ultrasonography of the abdomen, CT of the chest for those with initial Stage IV disease, and chest X-ray for patients with Stage I-III disease, as well as urine analysis and serum blood urea nitrogen and creatinine levels.
Data was analyzed using the SPSS software version 22 (SPSS Inc., Chicago, IL, USA). Kaplan-Meier survival curves were generated to estimate overall survival (OS), event free survival (EFS), and Stage specific survival estimates. OS was defined as time from initial diagnosis to time of death from any cause or to most recent follow-up. EFS was defined as time from initial diagnosis to first relapse, death from any cause, or most recent follow-up, whichever occurred first.
Results
Thirty-five children were diagnosed with nephroblastoma and represented 4% of all patients diagnosed with cancer during the study period. Patient characteristics are shown in Table 1 . Male to female ratio was 1:1.7, and the mean age at diagnosis was 3.9 ± 3.1 years (median 3 years, range, 0.6-16 years). Stage distribution is shown in Table 1 ; local Stage III disease was due to positive abdominal lymph nodes by histology in six patients (3 of whom also had metastatic disease), intra-operative tumor spillage in two patients, nonresectable tumor in five patients, pre-operative tumor rupture due to trauma in one patient, and upstaging due to incomplete operation prior to referral in two patients. Three patients had tumor thrombus involving the inferior vena cava at diagnosis, and one patient had thrombus reaching renal vein but with patent inferior vena cava.
Twenty-three patients (66%) had an upfront nephrectomy followed by Stage specific chemotherapy and radiotherapy as per the North American NWTS-5 protocol. Eleven patients (31%) had an upfront biopsy followed by definitive surgery at a median time of 6 weeks after initiation of chemotherapy (range, 2-15 weeks). One patient died due to disseminated intravascular coagulation prior to timing of surgery. All remaining patients underwent successful tumor resection. Thirty patients underwent unilateral nephrectomy, and two of them also required partial diaphragmatic resection to achieve negative margins. For the four patients with bilateral tumors, two underwent bilateral partial nephrectomies, and two required unilateral radical nephrectomy and partial nephrectomy on the other side. One patient had diffuse anaplasia; all others had favorable histology tumors. Eight patients received whole abdominal radiation therapy, and six received flank/tumor bed radiation. Five patients received radiation therapy to the lungs, and one received additional radiation therapy to liver metastases. Planned chemotherapy was administered successfully, with minimal delays in schedule. Complications of chemotherapy are shown in Table 2 . Surgical complications were infrequent: two patients developed functional intestinal obstruction, which was managed conservatively and resolved without long-term sequelae. In general, patients were observed in the pediatric intensive care unit for at least 2 days after nephrectomy. Of note, one patient developed chronic renal failure during treatment, due to focal segmental glomerulosclerosis occurring in the remaining noninvolved kidney. This child was found to have Denys-Drash syndrome using WT1 gene mutation analysis, and is currently on chronic dialysis awaiting renal transplantation.
The treatment outcomes are shown in Table 2 . At the time of analysis, 30 patients (86%) were alive; all were free of disease at a median follow-up time of 58 months from diagnosis (range, 23-134 months). Four patients had disease relapse at a median time of 8.8 months (range, 7.1-12.2 months) from initial diagnosis. Notably, all four patients who had relapse had initial metastatic (Stage IV) disease. Relapse occurred in the lungs in all four patients; two patients also had synchronous liver metastases and one had synchronous metastasis to the uterus. All four patients who relapsed died due to disease progression despite second-line therapy. The 3-year OS and EFS estimates for all analyzed patients were 88.6% and 85.7%, respectively ( Figure 1A and B). When analyzed by Stage, patients with Stage I, II, and V disease had 100% 3-year OS, whereas patients with Stage III disease had a 3-year OS of 90%, and those with Stage IV disease had a 3-year OS of 67% ( Figure 1C ). EFS rates followed a similar pattern, with 3-year EFS for patients with Stages I, II, and V disease at 100%, Stage III disease at 90%, and Stage IV disease at 55.6%. [27] [28] [29] [30] [31] [32] . In our series, the 3-year EFS and OS were 85.7% and 88.6% respectively. Although we describe a small number of patients limiting statistical comparisons, it seems that our experience shows similar outcome rates for patients with Stage I, II, III, and V disease, while patients with metastatic disease fared worse than published results from cooperative group trials. In general, patient characteristics at presentation did not differ from those published from other centers, taking the variable sample sizes into account. We observed a female preponderance, similar to what has been observed in the NWTS and SIOP studies [24, 26] . The median age at presentation was 36 months, which is comparable to what has been observed in other studies [9, [11] [12] [13] [15] [16] [17] [18] 33, 34] . The right kidney was more commonly affected than the left in our study. In our cohort of patients, treatment was not interrupted and there was no abandonment-a very important consideration that affects Note. Data are presented as n (%).
a All patients who relapsed died of disease progression. outcome in developing and middle-income countries [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . This is likely due to the fact that all financial barriers were resolved by complete financial coverage of treatment costs by a local fundraising body, which allowed patients with poor socioeconomic status and lack of third-party insurance to continue therapy without major interruptions. While the apparently worse outcome of children with Stage IV disease in our study could be due to a difference in tumor biology, it should be kept in mind that the small number of patients analyzed limits the significance of this observed difference.
Other issues in treatment allocation and delivery were noted that deserve mentioning. Firstly, upstaging was necessary in two of 35 patients (6%) due to inappropriate surgery before patient referral to the oncologist. This upstaging resulted in treatment as Stage III disease, with more intensive chemotherapy (DD4A regimen) and whole abdomen radiation therapy. Even after accounting for patients who had their disease upstaged due to inadequate or unclear surgical details prior to referral, we still had a high rate of patients who presented with late Stage disease (III and IV), compared with developed countries [17, 26, 27, 29] . This is in fact similar to what has been observed in most low-and middle-income countries [7, 9, 11, 12, 14, 16, 33, 35] . Whether this is an indication of delayed presentation or more aggressive tumor biology, still needs to be determined.
We also noted that all patients in our series had disease staging based on chest CT and not chest X-ray, and all those with lung nodules detected with CT scan received Stage IVdirected therapy (DD-4A) as well as radiation therapy to the lungs. While one study showed that three-drug regimen for CT-only metastases can improve EFS but not OS [36] , in other studies patients with CT-only lung metastases in the setting of low-stage primary tumors were shown to be adequately treated with a two-drug regimen [37, 38] . Most patients with metastases, however, had local Stage III disease, and therefore treatment regimen included anthracyclines. The benefit of lung radiation in patients with CT-only lung metastases is still unclear [36, 38] and may contribute to significant long-term side effects [39] [40] [41] . Thus, further efforts should be made to ensure discussion of such issues in multidisciplinary meetings when individualized therapy decisions are made.
Finally, the rate of bilateral tumors (11% of our patients) seems higher than that observed in the NWTS and SIOP cohorts, as well as other reported series [7, 9, [12] [13] [14] 16, 19, 29, 3, 32, [34] [35] [36] 42] . While the reasons for this finding are unclear, and taking into consideration the limitation of our small number of patients, it does raise questions regarding possible predisposition conditions to bilateral tumors in this population and warrants further future assessment. In our series, patients with Stage V tumors did very well, which compares favorably to published results [12,13,16,29,31,3 2,34,42-44] . Three of these patients received DD4A regimen and one received EE-4A regimen. All had complete tumor resection consisting of either bilateral partial nephrectomies or nephrectomy on one side and partial nephrectomy on the other. None received radiation therapy, and all four are in continued Complete Remission (CR) with normal renal function.
Conclusion
Although similar to other developing countries, more than half of our patients presented with late Stage disease (III and IV) and the outcome of patients in this study approached that reported in cooperative trials in developed countries. This likely represents the effects of a multidisciplinary approach to management, availability of a specialized pediatric oncology surgeon, availability of prompt supportive care measures, and financial coverage of treatment contributing to low abandonment rates. Earlier referral of patients to a tertiary care setting, prior to attempted surgery, would be expected to further improve outcome and minimize over-staging of such patients.
